S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches

Edesa Biotech (EDSA) Competitors

$4.87
+0.25 (+5.41%)
(As of 03/1/2024 ET)

EDSA vs. INDP, LGVN, SEEL, FBRX, KLDO, LIPO, LSTA, SNPX, ONCT, and ESLA

Should you be buying Edesa Biotech stock or one of its competitors? The main competitors of Edesa Biotech include Indaptus Therapeutics (INDP), Longeveron (LGVN), Seelos Therapeutics (SEEL), Forte Biosciences (FBRX), Kaleido Biosciences (KLDO), Lipella Pharmaceuticals (LIPO), Lisata Therapeutics (LSTA), Synaptogenix (SNPX), Oncternal Therapeutics (ONCT), and Estrella Immunopharma (ESLA). These companies are all part of the "medical" sector.

Edesa Biotech vs.

Indaptus Therapeutics (NASDAQ:INDP) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Indaptus TherapeuticsN/AN/A-$14.32M-$1.81-1.15
Edesa BiotechN/AN/A-$8.37MN/AN/A

Indaptus Therapeutics has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, Edesa Biotech has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500.

Indaptus Therapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 474.16%. Edesa Biotech has a consensus price target of $39.00, suggesting a potential upside of 700.82%. Given Indaptus Therapeutics' higher possible upside, analysts clearly believe Edesa Biotech is more favorable than Indaptus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Indaptus Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Edesa Biotech
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Edesa Biotech received 16 more outperform votes than Indaptus Therapeutics when rated by MarketBeat users. However, 81.82% of users gave Indaptus Therapeutics an outperform vote while only 75.76% of users gave Edesa Biotech an outperform vote.

CompanyUnderperformOutperform
Indaptus TherapeuticsOutperform Votes
9
81.82%
Underperform Votes
2
18.18%
Edesa BiotechOutperform Votes
25
75.76%
Underperform Votes
8
24.24%

21.2% of Indaptus Therapeutics shares are held by institutional investors. Comparatively, 31.3% of Edesa Biotech shares are held by institutional investors. 27.1% of Indaptus Therapeutics shares are held by insiders. Comparatively, 26.5% of Edesa Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Indaptus Therapeutics had 1 more articles in the media than Edesa Biotech. MarketBeat recorded 3 mentions for Indaptus Therapeutics and 2 mentions for Edesa Biotech. Indaptus Therapeutics' average media sentiment score of 1.44 beat Edesa Biotech's score of 0.30 indicating that Edesa Biotech is being referred to more favorably in the news media.

Company Overall Sentiment
Indaptus Therapeutics Neutral
Edesa Biotech Positive

Edesa Biotech's return on equity of -75.59% beat Indaptus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Indaptus TherapeuticsN/A -75.59% -67.12%
Edesa Biotech N/A -103.78%-83.85%

Summary

Indaptus Therapeutics and Edesa Biotech tied by winning 6 of the 12 factors compared between the two stocks.


Get Edesa Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for EDSA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EDSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EDSA vs. The Competition

MetricEdesa BiotechPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$15.44M$6.81B$5.03B$7.61B
Dividend YieldN/A2.82%2.81%3.87%
P/E RatioN/A19.05268.4518.95
Price / SalesN/A216.173,026.4273.94
Price / CashN/A19.1098.1954.91
Price / Book2.654.934.594.72
Net Income-$8.37M$160.19M$114.92M$211.49M
7 Day Performance-2.40%7.57%5.66%3.35%
1 Month Performance7.27%14.80%10.47%6.19%
1 Year Performance-49.95%8.21%13.91%9.63%

Edesa Biotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INDP
Indaptus Therapeutics
2.6386 of 5 stars
$1.94
+1.0%
$12.00
+518.6%
+22.9%$16.30MN/A-1.076Short Interest ↑
LGVN
Longeveron
2.956 of 5 stars
$0.58
+7.4%
$9.25
+1,498.1%
-85.1%$14.53M$1.22M-0.5919Short Interest ↓
Analyst Revision
News Coverage
Gap Up
SEEL
Seelos Therapeutics
3.3824 of 5 stars
$0.99
+2.1%
$70.00
+6,969.3%
-94.3%$7.30MN/A0.0016Short Interest ↓
Gap Down
FBRX
Forte Biosciences
1.068 of 5 stars
$0.69
-1.4%
N/A-27.6%$24.89MN/A-0.559Short Interest ↑
KLDO
Kaleido Biosciences
0 of 5 stars
N/AN/AN/A$6.39M$1.10M0.0076High Trading Volume
LIPO
Lipella Pharmaceuticals
0 of 5 stars
$1.05
+3.0%
N/A-52.1%$6.32M$180,000.000.005Short Interest ↑
News Coverage
LSTA
Lisata Therapeutics
2.8662 of 5 stars
$3.18
+5.3%
$15.00
+371.7%
+2.3%$25.89MN/A-1.1927Analyst Report
News Coverage
Gap Down
SNPX
Synaptogenix
0 of 5 stars
$0.20
+5.2%
N/A-80.1%$4.10MN/A-0.195Short Interest ↑
ONCT
Oncternal Therapeutics
3.3576 of 5 stars
$9.66
+4.3%
$69.00
+614.3%
-44.0%$28.50M$1.49M-0.6730Upcoming Earnings
News Coverage
ESLA
Estrella Immunopharma
0 of 5 stars
$1.04
-1.9%
N/AN/A$38.07MN/A0.00N/AShort Interest ↑
Positive News
Gap Down

Related Companies and Tools

This page (NASDAQ:EDSA) was last updated on 3/2/2024 by MarketBeat.com Staff